Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Subcutaneous vs Intravenous Belantamab in Multiple Myeloma (DynaMMic-2)
NCT07742527Phase 1Not yet recruiting
- Sponsor
- GSK
- Start
- Oct 2026
- Primary completion
- Aug 2027
01
Overview
Phase 1, randomised, open-label trial of belantamab in multiple myeloma (MM) (2 arms), sponsored by GSK. Primary endpoints: Bioavailability of belantamab at 42 weeks, Maximum observed plasma concentration of belantamab at 42 weeks and 5 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
belantamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07742527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07742527.